The pharmacodynamic profile of ertapenem was evaluated in a neutropenic mouse thigh
infection model. Extended-spectrum beta-lactamase (ESBL)-positive and ESBL-negative …

The purpose of this study was to examine the in vivo efficacies of meropenem and
ertapenem against extended-spectrum-β-lactamase (ESBL)-producing isolates with a wide …

The objective of this study was to determine the susceptibility breakpoint of a new
carbapenem, ertapenem (MK-0826), against Streptococcus pneumoniae strains based on …

Abstract Background Carbapenem-resistant Enterobacterales (CRE) and carbapenemase-
producing Enterobacterales (CPE) are difficult to treat and are a serious public health threat …

Objectives We assessed the pharmacodynamic activity of ertapenem against Escherichia
coli with reduced susceptibility (MIC 0.12–0.5 mg/L), intermediate resistance (MIC 1.0 mg/L) …

Ertapenem is a new 1-β-methyl carbapenem, stable to dehydropeptidase, which binds
preferable to penicillin-binding proteins (PBP) 2 and 3. Ertapenem has a broad antibacterial …

Objectives Ertapenem has proven to be an effective antimicrobial; however, increasing
enzyme-mediated resistance has been noted. Combination with zidebactam, a β-lactam …

Ertapenem (INVANZ) is a new once-a-day parenteral β-lactam antimicrobial shown to be
effective as a single agent for treatment of various community-acquired and mixed infections …

The In vitro activity of ertapenem against bacterial pathogens isolated from patients with
moderate to severe complicated intra-abdominal, complicated skin/skin structure, acute …

The objective of these studies was to evaluate the exposures of meropenem and
vaborbactam that would produce antibacterial activity and prevent resistance development …